Immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) antibodies and programmed cell death 1 ligand 1 (PD-L1) antibodies, are potential therapeutic strategies for the treatment of HCC (Table 2). Here, PDCD1 is linked to hepatocellular carcinoma.